Table 2.
Clinical and neuropathological data of subjects in the cleared tissue study.
| Case | Group | Age (y) | Sex | PMT (h) | Brain weight (g) | APOE Genotype | Aβ plaque score (55) | NFT stage (7) | Neuritic plaque score (CERAD (36) | ABC score (26) | CAA (54) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | Type | Stage | ||||||||||
| 2016‐137 | CTRL | 77 | M | 12.8 | 1581 | E3/E3 | 2 | III | 0 | 1 | 2 | 0 | n.d. | n.d. |
| 2017‐003 | CTRL | 96 | F | 6.25 | 1135 | E3/E3 | 3 | III | 1 | 2 | 1 | 1 | 2 | 1 |
| 2017‐005 | CTRL | 60 | F | 5.5 | 1215 | E3/E3 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 1 |
| 2017‐043 | CTRL | 80 | M | 9.5 | 1460 | E2/E3 | 0 | II | 0 | 0 | 1 | 0 | n.d. | n.d. |
| 2016‐120 | AD | 88 | F | 6.67 | 905 | E2/E2 | 5 | V | 3 | 3 | 3 | 3 | 1 | 2 |
| 2016‐129 | AD | 90 | F | 9 | 1275 | E3/E4 | 4 | IV | 1 | 3 | 2 | 1 | 1 | 1 |
| 2016‐130 | AD | 73 | M | 5.83 | 1300 | E3/E3 | 5 | VI | 3 | 3 | 3 | 3 | 2 | 1 |
| 2016‐132 | AD | 66 | F | 8 | 1115 | E3/E3 | 5 | VI | 3 | 3 | 3 | 3 | 2 | 1 |
| 2017‐018 | AD | 65 | M | 7.83 | 1305 | E3/E3 | 4 | V | 3 | 2 | 3 | 3 | 1 | 2 |
| 2017‐024 | AD | 59 | M | 6.5 | 1305 | E4/E4 | 5 | V | 3 | 3 | 3 | 3 | 1 | 3 |
| 2017‐030 | AD | 80 | M | 10.8 | 1455 | E3/E3 | 5 | VI | 3 | 3 | 3 | 3 | 1 | 2 |
| 2017‐035 | AD | 95 | F | 6.58 | 890 | E3/E4 | 5 | VI | 3 | 3 | 3 | 3 | 1 | 1 |
| 2017‐039 | AD | 88 | M | 8.58 | 1445 | E3/E3 | 5 | V | 3 | 3 | 3 | 3 | 1 | 1 |
| 2017‐045 | AD | 61 | F | 6.83 | 920 | E2/E4 | 5 | VI | 3 | 3 | 3 | 3 | 1 | 1 |
| 2017‐049 | AD | 96 | M | 4.42 | 1095 | E3/E3 | 5 | V | 3 | 3 | 3 | 3 | 2 | 1 |
| 2017‐051 | AD | 94 | M | 6.75 | 1107 | E4/E4 | 5 | V | 3 | 3 | 3 | 3 | 2 | 1 |
| 2017‐054 | AD | 69 | F | 6.17 | 1065 | E3/E3 | 5 | VI | 3 | 3 | 3 | 3 | 1 | 1 |
PMT = post‐mortem time; NFT = neurofibrillary tangles; CAA = cerebral amyloid angiopathy; Neuritic plaque score (CERAD) = 0, absent; 1, sparse; 2, moderate; 3, severe; n.d. = not determined.